7770 Regents Roas
Suite 113-618
San Diego, CA 92122
United States
858 550 1900
https://www.evofem.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 37
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Ms. Saundra Pelletier | Interim Chair, President & CEO | 1,52M | N/D | 1970 |
Ms. Ivy Zhang | CFO & Secretary | 438,85k | N/D | 1979 |
Ms. Amy Raskopf | Senior Vice President of Investor Relations | N/D | N/D | N/D |
Kathy Gallo-Doyle | Vice President of Sales | N/D | N/D | N/D |
Ms. Rachael Hildebrandt P.H.R. | Head of Human Resources | N/D | N/D | N/D |
Ms. Ellen Thomas | Chief of Staff | N/D | N/D | N/D |
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
L'ISS Governance QualityScore di Evofem Biosciences, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.